TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04873323
Drug: TS-142
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of TS-142 10 mg or TS-142 30 mg in the morning under fasting in each period
Study: NCT05938088
Drug: Arm II (placebo group)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is performed in the same way as Arm l.
Study: NCT05814770
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The participants were randomized in an equal ratio to receive spironolactone 20 mg twice daily. Patients received the initial dose of study drug for the first 4 weeks of randomized treatment period. Thereafter, the dose of study medication was not changed for patients with adequate BP control. For patients not meeting BP \< 140/90 mmHg at week 4, the dose of study medication was increased to spironolactone 40 mg twice daily. If BP \> 160/110 mmHg at the time of 8 weeks follow-up, nifedipine 30mg once day was added.
Study: NCT06095973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depending on the cohort, volume will be varied to administer. Volume to be matched with the active investigational drug in the respective cohort.
Study: NCT04873323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of TS-142 placebo in the morning under fasting in each period
Study: NCT06649747
Drug: AFA-281
Normalized name: ADAPTER,ASPIRA/FLUSH,LUER URESIL AFA-LL
Approvals — FDA: no, EMA: no, PMDA: no
Description: A small molecule, orally available
Study: NCT05441150
Drug: 0.9% NaCl infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same dose of 0.9% NaCl infusion as the dose of ketamine for Control Group.
Study: NCT06702332
Drug: MSD-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSD-001 is being developed as part of future two-agent combination treatment approaches for the management of mental health indications
Study: NCT06702332
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT05535673
Drug: ThisCART19A
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this study, allogeneic anti-CD19 CAR-T cell (ThisCART19A) injection is used to treat patients with refractory or relapsed CD19 positive B cell Lymphoma.
Study: NCT06324851
Drug: Ethinylestradiol / Dienogest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Ethinylestradiol/Dienogest at any time of the menstrual cycle
Study: NCT05930925
Drug: [phenyl-14C]ARV-471
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of \[phenyl-14C\]ARV-471 by mouth
Study: NCT05930925
Drug: [oxoisoindolin-14C]ARV-471
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of \[oxoisoindolin-14C\]ARV-471 by mouth
Study: NCT05416931
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application to painful area
Study: NCT05619289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-time, oral dose of 6 inert capsules matched to the active comparator
Study: NCT06625671
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06043310
Drug: Nω-nitro-L-arginine methyl ester (L-NAME)
Normalized name: methyl L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME will be infused locally through microdialysis catheters.
Study: NCT06043310
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACh will be infused locally through microdialysis catheters.
Study: NCT05694364
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is a nitrogen mustard-derivative, polyfunctional alkylating agent given prior to lymphodepletion.
Study: NCT05106972
Drug: UC-MSC infusion
Normalized name: Astri-UC
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC-MSC infusion by introvenus
Study: NCT04742153
Drug: MRG002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated intravenously
Study: NCT06099873
Drug: ZX-7101A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day1 Take one tablet of ZX-7101A orally once (specification: 40mg/ tablet) with appropriate amount of warm water
Study: NCT06099873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day1 Take one tablet of Placebo orally once with appropriate amount of warm water
Study: NCT05022004
Drug: Azopt®
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks
Study: NCT04631471
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing dose of matching placebo from 6 capsules per day to 10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
Study: NCT06321484
Drug: Interleukin 2
Normalized name: Recombinant interleukin 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose subcutaneous IL-2 will be administered every other day for 5 doses after CIML NK cell infusion
Study: NCT05707845
Drug: Medical treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs).
Study: NCT05238896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 4 mg/d, oral route for 7 days, then Baricitinib 4 mg/d oral route for 5 weeks
Study: NCT04628793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
Study: NCT04518293
Drug: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single pill
Study: NCT04518293
Drug: telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Signle pill
Study: NCT06186414
Drug: SIM0237
Approvals — FDA: no, EMA: no, PMDA: no
Description: RD level of SIM0237 will be administered as a single agent for evaluation
Study: NCT04518293
Drug: Telmisartan 20 mg/indapamide 1.25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04518293
Drug: telmisartan 40 mg/indapamide 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04518293
Drug: Amlodipine 2.5 mg/indapamide 1.25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04518293
Drug: amlodipine 5 mg/indapamide 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT06205316
Drug: Antiandrogen Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive ADT
Study: NCT04760314
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04760314
Drug: Topical Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-applied
Study: NCT06636617
Drug: 3.70 GBq (100 mCi) of 177Lu-JH04
Approvals — FDA: no, EMA: no, PMDA: no
Description: All 3 patients were intravenous injected with single dose 3.70 GBq (100 mCi) of 177Lu-JH04.
Study: NCT06636617
Drug: 5.55 GBq (150 mCi) of 177Lu-JH04
Approvals — FDA: no, EMA: no, PMDA: no
Description: All 3 patients were intravenous injected with single 5.55 GBq (150 mCi) of 177Lu-JH04
Study: NCT06636617
Drug: 7.40 GBq (200 mCi) of 177Lu-JH04
Approvals — FDA: no, EMA: no, PMDA: no
Description: All 3 patients were intravenous injected with single 7.40 GBq (200 mCi) of 177Lu-JH04
Study: NCT05716607
Drug: OD dual-release Hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with once-daily dual-release hydrocortisone
Study: NCT05716607
Drug: TID Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment with thrice-daily conventional immediate-release hydrocortisone
Study: NCT06628206
Drug: LPX-TI641
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution administered QD for 28 consecutive days
Study: NCT06628206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug is LPX-TI641 oral solution. Placebo an identical oral solution without the LPX-TI641.
Study: NCT06627088
Drug: LY4100511 (DC-853)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered oral dose
Study: NCT06627088
Drug: [14C]-LY4100511 (DC-853) Administered oral dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered oral dose
Study: NCT06627088
Drug: [14C]-LY4100511 (DC-853)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV infusion
Study: NCT04720417
Drug: Raf/MEK Inhibitor VS-6766
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04951856
Drug: Standard of care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: management as recommended in ESC/EAS 2019 guidelines, within reimbursement criteria
Study: NCT05677451
Drug: LOU064 (blinded)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOU064 (blinded) active treatment
Study: NCT05677451
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching active drug
Study: NCT06692764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg (Placebo). Participants will receive bottles, with placebo tablets. Participants will take 1 tablet from each bottle on each scheduled day of study intervention, which will provide the placebo dose.
Study: NCT06692764
Drug: AZD0780
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1 Participants will receive three bottles, each containing 35 tablets:~* 1 bottle of dose a AZD0780 tablets~* 1 bottle of dose b AZD0780 tablets~* 1 bottle of dose c AZD0780 tablets Participants will take 1 tablet from each bottle on each scheduled day of study intervention, which will provide the AZD0780 dose.
Study: NCT06692426
Drug: MyoPAXon
Approvals — FDA: no, EMA: no, PMDA: no
Description: MyoPAXon is a CD54+ allogeneic muscle progenitor cell product derived from the iPSC line LiPSC-ER2.2
Study: NCT04528082
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive the matching placebo orally.
Study: NCT04893096
Drug: MOR202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will be treated for 24 weeks and received a total of 9 doses. During the first treatment cycle, MOR202 will be administered weekly. For the following 5 months, patients will receive one dose every 4 weeks.
Study: NCT06533657
Drug: Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer patients meeting eligibility criteria will receive Trichomylin® and self-titrate to effective dose.
Study: NCT05895825
Drug: EOC237
Approvals — FDA: no, EMA: no, PMDA: no
Description: EOC237 for orally
Study: NCT06685068
Drug: GEN1286
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05890963
Drug: 10E8.4/iMab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity. 10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.
Study: NCT05890963
Drug: VRC07-523LS
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC07-523LS is an engineered variant of VRC01, a bNAb that targets the CD4 binding site of the HIV-1 envelope. VRC07-523LS will be administered IV at the 1200mg dose to participants in Step 1 per the SOE.
Study: NCT06326463
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day -3 and Day-2~REST DAY, -1
Study: NCT06625931
Drug: NTCB01-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 Days infusion
Study: NCT06625931
Drug: NTCB-P
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 Days infusion
Study: NCT05645276
Drug: AK129 IV infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK129 is administered intravenously according to the frequency and dosage of administration at different stages.
Study: NCT06693934
Drug: Medication
Normalized name: Acne Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse and medical consultations and subsidized medications (metformin, statin, ARB) will be provided to the high risk progressor, IGT and diabetes groups as appropriate for control of glucose and CKM risk factors.
Study: NCT06695026
Drug: RZ-001 Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: RZ-001 Dose 1 and VGCV, Atezolizumab/Bevacizumab
Study: NCT06695026
Drug: RZ-001 Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: RZ-001 Dose 2 and VGCV, Atezolizumab/Bevacizumab
Study: NCT06695026
Drug: RZ-001 Dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: RZ-001 Dose 3 and VGCV, Atezolizumab/Bevacizumab
Study: NCT06630858
Drug: Patient Controlled Analgesia (IV PCA)
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine-PCA will be applied postoperatively for 24 hours . IV-PCA: The requested dose will be 1mg morphine, the lock-in time will be 6 minutes, the 4-hour limit will be 20 mg morphine.
Study: NCT06630299
Drug: Antiretroviral Combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 or 3 antiretrovirals (ARVs) administered as defined by the investigator, according to the prescribing information.
Study: NCT06629259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet once daily
Study: NCT06629779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral continuous
Study: NCT04894474
Drug: Placebo intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous
Study: NCT04894474
Drug: Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation
Study: NCT05695859
Drug: 99mTc-DARPinG3 SPECT/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection
Study: NCT06687070
Drug: PLD
Normalized name: PLD1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected on the first day of each cycle, every 28 days as a cycle.
Study: NCT04840394
Drug: BDB018
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDB018 is an immunotherapy agent.
Study: NCT04803786
Drug: Transition from Xyrem to Xywav
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a single-group non-interventional study where participant's transitioning from Xyrem to Xywav will be observed. Investigational product (IP) or drug support or requested changes to their medication will not be provided to participants by Jazz Pharmaceuticals. The Xyrem and Xywav that the participants will take will be provided by the participant's health care provider.
Study: NCT05202366
Drug: CGB-400 Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGB-400 Gel contains two main ingredients: geranic acid and choline. Geranic acid, a naturally occurring essential oil/terpenoid, is a key ingredient in lemon grass and is also found in other natural materials such as cardamom. The other main ingredient in CAGE is choline, which is an essential dietary component and found in foods as free choline and as several esterified forms such as phosphocholine and phosphatidylcholine.
Study: NCT05590234
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of normal saline 0.9%.
Study: NCT04997837
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CapeOx: 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
Study: NCT04997837
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine 625mg/m2 bid orally with radiotherapy; ORegafur-gimeracil-oteracil potassium combination drug 40-60mg bid orally with radiotherapy
Study: NCT06004830
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will receive a prescription for spironolactone and will meet with a clinical pharmacist and addiction psychiatrist for further support
Study: NCT04567420
Drug: Adjuvant Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care
Study: NCT06005714
Drug: Mindeudesivir hydrobromide tablets and Clarithromycin tablets
Normalized name: clarithromycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindeudesivir hydrobromide tablets are administered once at D1 and D4, and clarithromycin tablets are administered twice from D1 to D10.
Study: NCT05827146
Drug: Hepalatide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
Study: NCT05827146
Drug: Hepalatide Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
Study: NCT04539808
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04539808
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04539808
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06625307
Drug: NNC0537-1482
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via subcutaneous route
Study: NCT06625307
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via subcutaneous route
Study: NCT06000891
Drug: ZP7570
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 once-weekly subcutaneous injections in Part 1. 28 once-weekly subcutaneous injections in Part 2.
Study: NCT06000891
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 once-weekly subcutaneous injections in Part 1. 28 once-weekly subcutaneous injections in Part 2.
Study: NCT06711991
Drug: TQC3927 powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQC3927 is a targeted inhibitor
Study: NCT04611529
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 400mg
Study: NCT04611529
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 1% gel 4gm
Study: NCT06709014
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule by mouth once daily for 18 months
Study: NCT04772365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be subcutaneously administered with different dose levels;
Study: NCT06627322
Drug: Triple-combination therapy
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: Metformin/SGLT2i/DPP-4i-based triple-cobmination therapy, or Group 3: Metformin/SGLT2i/Thiazolidinedione-based triple-cobmination therapy Any oral antiglycemic drugs on the market.
Study: NCT06453447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet (cellulose) PO once daily for 14 days starting day of surgery
Study: NCT05468957
Drug: Statseal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
Study: NCT06686628
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study: NCT05908383
Drug: GMDTC for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMDTC for injection with a specification of 0.5g/vial, 250mg,500mg,850mg,1200mg,1600mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
Study: NCT06192446
Drug: Survey using a questionnaire.
Approvals — FDA: no, EMA: no, PMDA: no
Description: An observational study conducted in a cross-sectional manner using a questionnaire.
Study: NCT05463679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match enzastaurin 500 mg QD orally in the form of four 125 mg tablets with background standard of care
Study: NCT05097976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 sugar tablets beginning on POD 1 with standard management
Study: NCT06650761
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 3 infusions of Normal Saline
Study: NCT05628363
Drug: Androgen deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) will be administered to study patients according to institutional standard. Patients should initiate ADT beginning no sooner than 60 days prior to start of radiation. ADT is defined as a GnRH agonist/antagonist (leuprolide, goserelin, degarelix, or relugolix). Patients treated with leuprolide, goserelin, or degarelix should also receive an androgen receptor antagonist (flutamide or bicalutamide) for 30 days from the start of GnRH agonist/antagonist or until the end of radiation, depending on institutional standard and physician preference.~Agent selection is per treating physician discretion and will be administered per institutional standard and FDA-approved labeling.
Study: NCT04795596
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: second line chemotherapy according to investigator's choice